TITLE

Visceral Fat as Target of Highly Active Antiretroviral Therapy-Associated Metabolic Syndrome

AUTHOR(S)
Giuseppe Barbaro
PUB. DATE
July 2007
SOURCE
Current Pharmaceutical Design;Jul2007, Vol. 13 Issue 21, p2208
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
HIV-associated lipodystrophy or lipoatrophy, unreported before the introduction of highly active antiretroviral therapy (HAART), was first described in 1998, and has a prevalence ranging from 18% to 83%. As in genetic lipodystrophy syndromes, fat redistribution may precede the development of metabolic complications (dyslipidemia, insulin resistance) in HIV-infected patients receiving HAART. The pathogenesis of HAART-associated lipodystrophy and metabolic syndrome is complex and a number of factors are involved, including direct effects of HAART on lipid metabolism, endothelial and adipocyte cell function, and mitochondria.Protease inhibitors are responsible for a decrease in cytoplasmic retinoic-acid protein-1, in low density lipoprotein-receptor-related protein and in peroxisome proliferator activated receptor type-gamma. Nucleoside reverse transcriptase inhibitors, and thymidine analogues, are responsible for mitochondrial dysfunction as demonstrated by a decrease in subcutaneous adipose tissue mitochondrial DNA content. Both phenomena are responsible for a decreased differentiation of adipocytes, increased levels of free fatty acids and lipoatrophy. The increased levels of proinflammatory cytokines, such as tumor necrosis factor (TNF)-alpha and interleukin-6 may further contribute in development of lipodystrophy. TNF-alfa activates 11-beta-hydroxysteroid dehydrogenase type-1, which converts inactive cortisone to active cortisol, resulting in increased lipid accumulation in adipocytes and insulin resistance. HAART drugs and inflammatory cytokines are associated with a decrease in adiponectin. The levels of adiponectin and adiponectin-to-leptin ratio correlate positively with insulin resistance in HIV-infected patients with lipodystrophy. HAART-associated metabolic syndrome is an increasingly recognized clinical entity. The atherogenic profile of this syndrome may increase the risk of cardiovascular disease even in young HIV-infected patients. A better understanding of the molecular mechanisms responsible for this syndrome will lead to the discovery of new drugs that will reduce the incidence of lipodystrophy and related metabolic complications in HIV-infected patients receiving HAART.
ACCESSION #
25541614

 

Related Articles

  • Predictors of Visceral Leishmaniasis Relapse in HIV-Infected Patients: A Systematic Review. Cota, Gláucia F.; Sousa, Marcos R. de; Rabello, Ana // PLoS Neglected Tropical Diseases;Jun2011, Vol. 5 Issue 6, p1 

    Background and Objectives: Visceral leishmaniasis (VL) is a common complication in AIDS patients living in Leishmaniaendemic areas. Although antiretroviral therapy has changed the clinical course of HIV infection and its associated illnesses, the prevention of VL relapses remains a challenge for...

  • Bilateral pedal edema in an HIV patient: Lopinavir/Ritonavir-containing treatment regimen as a potential cause? Shihab, Hasan M.; Lutwama, Fred; Piloya, Theresa; Castelnuovo, Barbara; Kambugu, Andrew D.; Colebunders, Robert // Journal of Infection in Developing Countries;2009, Vol. 3 Issue 5, p405 

    A large number of patients are switched to second-line antiretroviral therapy, especially in resource limited settings. Lopinavir/Ritonavir is the main drug used in second-line treatment regimens. We describe a patient attending an HIV treatment centre in Kampala, Uganda, who presented with...

  • Increased risk of deep neck infection among HIV-infected patients in the era of highly active antiretroviral therapy--a population-based follow-up study. Ching-Feng Liu; Shih-Feng Weng; Yung-Song Lin; Chih-Sheng Lin; Ching-Feng Lien; Jhi-Joung Wang // BMC Infectious Diseases;2013, Vol. 13 Issue 1, p1 

    Background: Deep neck infections (DNIs) in HIV-infected patients often produce severe complications, even death. Data on the incidence rates and risks of DNI among HIV-infected patients are scarce, particularly with the widespread use of highly active antiretroviral therapy (HAART). We evaluated...

  • Factors associated with adherence to antiretroviral therapy in HIV-infected patients in Kathmandu District, Nepal. Shigdel, Rajesh; Klouman, Elise; Bhandari, Anita; Ahmed, Luai A. // HIV/AIDS - Research & Palliative Care;2014, Vol. 6, p109 

    Purpose: There are a high number of HIV-infected patients receiving antiretroviral therapy (ART) in the Kathmandu District of Nepal, but information on adherence and factors influencing it are scarce in this population. The present study aimed to estimate ART adherence among HIV-infected...

  • Improved Virological Outcomes in British Columbia Concomitant with Decreasing Incidence of HIV Type 1 Drug Resistance Detection. Gill, Vikram S.; Lima, Viviane D.; Wen Zhang; Wynhoven, Brian; Yip, Benita; Hogg, Robert S.; Montaner, Julio S. G.; Richard Harrigan, P. // Clinical Infectious Diseases;1/1/2010, Vol. 50 Issue 1, p98 

    Background. There have been limited studies evaluating temporal changes in the incidence of detection of drug resistance among human immunodeficiency virus type 1 (HIV-1) isolates and concomitant changes in plasma HIV load for treated individuals in a population-wide setting. Methods....

  • Pre-existing Minority Drug-Resistant HIV-1 Variants, Adherence, and Risk of Antiretroviral Treatment Failure. Paredes, Roger; Lalama, Christina M.; Ribaudo, Heather J.; Schackman, Bruce R.; Shikuma, Cecilia; Giguel, Francoise; Meyer III, William A.; Johnson, Victoria A.; Fiscus, Susan A.; D'Aquila, Richard T.; Gulick, Roy M.; Kuritzkes, Daniel R. // Journal of Infectious Diseases;3/1/2010, Vol. 201 Issue 5, p662 

    Background. The clinical relevance of detecting minority drug-resistant human immunodeficiency virus type 1 (HIV-1) variants is uncertain. Methods. To determine the effect of pre-existing minority nonnucleoside reverse-transcriptase inhibitor (NNRTI)-resistant variants on the risk of virologic...

  • Clinical Performance of a Dermal Filler Containing Natural Glycolic Acid and a Polylactic Acid Polymer. Tagle, Jorge M.; Macchetto, Pedro Cervantes; Páramo, Rosa Margarita Durán // Journal of Clinical & Aesthetic Dermatology;Feb2010, Vol. 3 Issue 2, p42 

    Lipoatrophy is a condition that affects certain individuals, most commonly those who are infected with the human immunodeficiency virus. Injectable fillers are used for the treatment of these dermal contour deformities to smooth dermal depressions formed by the loss of volume. These dermal...

  • HIV treatment prevents transmission of HIV.  // Africa Health;May2011, Vol. 33 Issue 4, p11 

    The article discusses the report from the US National Institutes of Health which found that an effective antiretroviral therapy regimen for HIV-positive person could prevent the risk of transmitting the virus to their uninfected sexual partner.

  • Detection of immunological treatment failure among HIV infected patients in Ethiopia: a retrospective cohort study. Teshome, Wondu; Tefera, Ambachew // BMC Immunology;9/17/2015, Vol. 16 Issue 1, p1 

    Background: Timely detection of treatment failure with subsequent switch to second-line regimen reduces mortality among HIV infected people on antiretroviral therapy (ART). This paper aims to investigate the detection of immunological treatment failure and switch rate to second line regimen in...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics